Correlation of High-Resolution X-Ray Micro-Computed Tomography with Bioluminescence Imaging of Multiple Myeloma Growth in a Xenograft Mouse Model by Postnov, Andrei A. et al.
Correlation of High-Resolution X-Ray Micro-Computed
Tomography with Bioluminescence Imaging of Multiple
Myeloma Growth in a Xenograft Mouse Model
Andrei A. Postnov Æ Henk Rozemuller Æ
Viviene Verwey Æ Henk Lokhorst Æ
Nora De Clerck Æ Anton C. Martens
Received: 27 October 2008/Accepted: 12 August 2009/Published online: 9 October 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Multiple myeloma (MM) is an incurable B-cell
neoplasia in which progressive skeletal lesions are a
characteristic feature. Earlier we established an animal
model for human MM in the immune-deﬁcient RAG2
-/-cc
-/-
mouse, in which the growth of luciferase-transduced MM
cells was visualized using noninvasive bioluminescence
imaging (BLI). This model appeared well suited to study
disease progression and response to therapy by identifying
the location of various foci of MM tumor growth scattered
throughout the skeleton and at subsequent time points the
quantitative assessment of the tumor load by using BLI.
We report here on the corresponding high-resolution X-ray
micro-computed tomographic (micro-CT) analysis to study
skeletal defects in the mice with full-blown MM. Several
anatomical derangements were observed, including
abnormalities in geometry and morphology, asymmetrical
bone structures, decreased overall density in the remaining
bone, loss of trabecular bone mass, destruction of the inner
microarchitecture, as well as cortical perforations. Using
the combination of BLI, micro-CT imaging, and immune-
histopathological techniques, we found a high correlation
between the micro-CT-identiﬁed lesions, exact tumor
location, and inﬁltration leading to structural lesions and
local bone deformation. This conﬁrms that this animal
model strongly resembles human MM and has the potential
for studying the biology of MM growth and for preclinical
testing of novel therapies for MM and for repair of MM-
induced bone lesions.
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Multiple myeloma (MM) is an incurable B-cell neoplasia,
of which one of the characteristics is focal growth of MM
cells scattered throughout the skeleton [1]. A typical fea-
ture of MM growth in the bone marrow environment in
patients is the development of lesions in bone structures
caused by secretion of cytokines that, among others, lead to
stimulation of osteoclast activity. Effective treatment of
MM should therefore not only be directed at inducing a
reduction of the tumor but also at inducing repair of the
MM-induced bone lesions. Preclinical testing of new
therapeutic strategies for the treatment of MM requires
animal models that closely resemble human disease in both
these aspects. Among murine models the 5T2MM model
[2] is highly valued because it strongly mimics human MM
growth, including its hallmark of osteolytic lesions that
were shown by micro-computed tomography (micro-CT) to
result in cortical perforations at the terminal stage of the
disease [3]. The murine model is also used not only for
unraveling basic biological processes in MM but also
for testing of potentially new therapeutic targets [4]. For
translational immunotherapy research in a humanized
model it is, however, desirable to establish a possible role
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for testing MM-speciﬁc T-cell clones and the T-cell
receptor transfer approach [6]. For preclinical testing of
novel treatment strategies a humanized animal model will
provide relevant data [7]. There are a limited number of
xenograft models of human myeloma in immune-deﬁcient
mice, e.g.—SCID mice [8–10], humanized SCID-Hu [11,
12], nonobese SCID mice [13–17], and SCID-Rab [18]—in
which several studies are ongoing that are aimed at iden-
tifying the illusive MM stem cell which is the ultimate
target that has to be eliminated to cure the disease [19].
While these models offer unique opportunities to study the
pathobiology of human MM in vivo, they have their lim-
itations for testing new therapeutics against human mye-
loma because as yet they are not suited for reproducible,
convenient, and sensitive monitoring of cytotoxic or
immunological therapies. In preclinical animal model
research it is important to select the appropriate model for
addressing speciﬁc research questions [7]. For MM studies
this implies having adequate analytical tools to detect and
quantify MM tumors and to analyze the typical MM-
associated pathological changes in the microenvironment.
We therefore developed a humanized murine model for
MM in the RAG2
-/-cc
-/- knock-out (KO) immune-deﬁcient
mouse [20], in which we showed that human MM cells can
successfully engraft since this mouse strain typically lacks
B, T, and NK cells [21, 22]. To monitor the in vivo MM
growth quantitatively, we injected RAG2
-/-cc
-/- mice
intravenously with luciferase gene–transduced MM cells.
For preclinical development of therapies based on immu-
nological targeting of myeloma cells with humanized
antibodies or minor HLA antigen–speciﬁc T cells, it is
important to use human myeloma cells already in the
preclinical phase. Therefore, we used U266 and RPMI
8226/S cell lines, which are both derived from myeloma
patients and have extensively been studied. Although the
long ex vivo culturing of these cells may have affected
typical MM characteristics, they retained the speciﬁc
behavior of homing only to the bone marrow environment
as well as the expression of CD138 [20]. The MM model
has been validated for such therapeutic interventions as
total-body irradiation and donor lymphocyte infusion, as
described earlier [20]. Here, we describe the results of a
micro-CT analysis of human MM-induced bone lesions in
this model. At sequential time points the outgrowth of MM
cells was visualized by noninvasive bioluminescence
imaging (BLI) in living mice. Whereas the BLI signal
indicates the presence of tumor cells, it does not show in
full detail what part of the skeleton is affected nor does it
identify the nature of the lesions caused by MM.
For a more focused insight into the defects caused by
MM, high-resolution X-ray micro- CT was applied post
mortem [23, 24]. Full-body scans were combined with an
extensive analysis of isolated bones. Micro-CT imaging
allowed exact localization and identiﬁcation of the ana-
tomical structures that were affected. Abnormalities in
geometry, morphology, and asymmetrical bone structures
were seen. Also, the ectopic calciﬁcation outside the skel-
eton was detected. A correlation was made between data
from micro-CT, presence of MM cells, and BLI to show the
potential of the combination of BLI and micro-CT.
Materials and Methods
Cell Lines and Cell Culturing
The human MM cell lines that we describe in this study are
U266 and RPMI-8226/S, of human origin (both obtained
from the American Tissue Culture Collection [ATCC])—
cultured, transduced with the luciferase-GFP gene, and
characterized as described earlier [20].
Transplantation of MM Cells into RAG2
-/-cc
-/- Mice
Immune-deﬁcient mice from the RAG2
-/-cc
-/- (double KO)
strain were used in the experiments at the age of 9–
14 weeks. Twenty-four hours before the injection of
freshly cultured MM, mice received total-body irradiation
(TBI, 3.0 Gy X-rays). MM cells (5 9 10
6) suspended in
200 ll PBS containing 0.1% BSA (GIBCO, Breda, The
Netherlands) were injected intravenously (i.v.) via the lat-
eral tail vein. The tumor load in the mice was determined
by weekly BLI measurements as described [20]. In case of
paralysis of the hind limbs or when the mice became
moribund, the experiment was terminated. The mice were
imaged in detail just before being killed by cervical dis-
location. Organs and skeletal parts were isolated and ﬁxed
in 4% formalin. As controls we killed mice of both sexes at
the same age. Organs and the skeleton were isolated and
ﬁxed in formalin.
BLI
A few minutes before BLI, the mice were anesthetized
by intramuscular (i.m.) injection of 50 ll of ketamine–
xylazine–atropine. One minute before imaging, the mice
received an intraperitoneal (i.p.) injection of 100 ll
7.5 mM D-luciferine (i.e., 125 mg/kg; Synchem Chemie,
Kassel, Germany) and were placed in a light-tight chamber.
Bioluminescence images were taken from both the ventral
and the dorsal sides of the mice using a cooled charge-
coupled device (CCCD) camera (Roper Scientiﬁc Prince-
ton Instrument, Trenton, NJ), ﬁtted to a light-tight chamber
and mounted with a 50-mm F1.2 Nikon lens, controlled by
the MetaVue Software package (Universal Imaging,
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for photon counting. The integrated light intensity of a
stack of 10 sequential 1-minute exposures was used to
quantify the amount of light emitted by the MM cells. A
low-intensity visible light image was made and used to
produce ‘‘overlay’’ images. The images were analyzed with
MetaMorph Imaging System software (Universal Imaging
Corporation).
Histopathological Examination
Femurs were ﬁxed, decalciﬁed in saturated EDTA for
7 days, and embedded in parafﬁn. Sections, 5 lm thick,
were stained with hematoxylin and eosin for histological
examination. For detection of human MM cells, sections
were labeled with anti-CD138 (Labvision, Fremont, CA).
As secondary antibody PowerVision Poly HRP-anti Rabbit
IgG (ImmunoLogic/Klinpath, Duiven, The Netherlands)
was used, followed by the peroxidase enzymatic reaction.
CD138 was used because FACS analysis of U266 and
RPMI 8226/S cells indicated that MM cells expressed this
CD marker in vitro as well as ex vivo in culture; it was
used for the in situ detection of foci of CD138-positive
MM cells on histological slides [20].
High-Resolution X-Ray Micro-CT
Micro-CT scans were obtained at the end of the experi-
ments after the death of the animals. Initially, in ﬁxed
animals the whole skeleton, except for the skull, was
scanned in an X-ray micro-CT system (Skyscan 1076,
Kontich, Belgium) in order to determine which parts of the
skeleton were affected. Both the X-ray source (focal spot
size 8 lm, energy range 20–100 keV) and the detector
(CCD camera 2.3kx4k) rotated around the animal. Scan-
ning time (12 minutes per scan of an area 18 mm long) and
conditions were selected to mimic an in vivo study of the
animals described earlier by our group [24]. Pixel size was
35 lm. A 90-kV tube voltage and a Ti ﬁlter in the beam
path were used. Rotation angle was 0.5
o. In total six to
eight successive scans (each 18 mm long) were acquired in
each animal to visualize the whole skeleton. Eleven dis-
eased and four control animals were scanned.
Based on the evaluation of the initial results of the full-
body scans, bones from the MM and control mice were
isolated and scanned by high-resolution X-ray micro-CT
(Skyscan 1072) with a pixel size of 13 lm. For more detailed
CT the right femur and tibia, sternum; pelvic region
including sacrum, ileum, sacral, lumbar and thoracic verte-
brae were selected for all mice regardless of the BLI signals.
F r o mt h e1 1m i c et h a tw es t u d i e dﬁ v et os e v e ns p e c i m e n s
were scanned in detail. In this micro-CT set-up, the camera
and X-ray source were ﬁxed, while the bones were mounted
on a rotating stage. Source parameters were 80 kV and 100
lA. A total of four frames were acquired with a 0.9 rotation
step, resulting in a scanning time of about 2 hours. In all
scans virtual cross sections were reconstructed by the
Feldkamp cone beam algorithm [25]. 3D models were built
by Skyscan software. Further details of both scanners were
published elsewhere (www.skyscan.be).
Results
Engraftment and Tumor Growth of MM Cell Lines
The cell lines U266 and RPMI-8226/S were selected
because they showed a characteristic outgrowth at multiple
sites scattered throughout the bone marrow compartment.
Following i.v. injection of 5 9 10
6 MM cells, the ﬁrst signs
of MM growth appeared after 3 weeks, illustrated by focal
areas of luciferase activity detected by BLI. The mice were
imaged every week, and photon counting of emitted light
provided a quantitative parameter to measure tumor load,
enabling the construction of tumor growth curves. Fig-
ure 1a shows the resulting growth curves for the RPMI-
8226/S cell line and Fig. 1b the curves for the U266 MM
cell line. Figure 1c, d depicts a representative mouse
(number 9), showing the location as well as the subsequent
outgrowth from weeks 3 through 15 at the ventral and dorsal
sides, respectively. The 2-weekly images show an increase
of the various foci with luciferase activity throughout the
skeleton of the mouse. As can be seen clearly, the ﬁrst signs
of MM growth are in the femur and tibia, followed by
luciferase activity at other locations, e.g., the pelvic region,
jaw, ribs, vertebrae, and sternum. The outgrowth of MM
tumors appeared to be restricted to the sites of initial
homing because in the course of MM development only
rarely were new sites of MM growth observed. BLI-nega-
tive skeleton parts showed no outgrowth of MM tumors. To
show the 2-weekly image in a single ﬁgure, we depicted the
subsequent images at different scaling to prevent oversat-
uration of the image (Fig. 1c, d). This is illustrative for the
large increase in local tumor load during tumor progression.
Toward the terminal phase of the disease we observed
emerging hind-leg paralysis in most of the animals, which
was the reason to kill the animals and to use them for post
mortem micro-CT analyses.
Micro-CT Imaging
Initially, full-body micro-CT revealed the location of
anatomical derangements in mice with MM.
A correlation was made between the BLI results and
micro-CT scanning of 11 complete skeletons of myeloma-
diseasedmice. Fifty-one positive BLI signals were detected,
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123whereas micro-CT showed that 53 regions in the skeleton
were affected.To evaluate the correlation ofBLI and micro-
CT, we summarized the correlation between the different
imaging signals (BLI and micro-CT) in Table 1. For the
femora and tibiae, a correlation in 19/22 was observed
between the two techniques and in the sternum a correlation
in 7/10 (one specimen was excluded due to the inability to
make scans of that area). For the pelvic (sacrum) area a
correlation was seen in 10/11 specimens examined, whereas
only 16/22 of the signals could be matched in the humera.
BLIsignalsinthechestarea,especiallytheribs,couldnotbe
conﬁrmed by micro-CT because these structures are too
small on the tomographic slices. It should also be noted that
the skull was not included in the micro-CT analysis.
Based on the results of the full-body scans, individual
bones were isolated and scanned at 13 lm pixel size. The
selected bones were the right femur and tibia, sternum,
ileum and sacrum including the sacral vertebrae, and
lumbar vertebrae. Results are illustrated by representative
examples. Both cortical bone and trabecular bone were
visualized in an isolated tibia from a control mouse
(Fig. 2a) and a diseased one (Fig. 2b). Figure 2a, b shows
virtual tomographic slices. In the MM mouse, trabecular
bone mass was reduced and part of the inner microarchi-
tecture of the bone disappeared. Overall density of the
remaining bone structures was smaller in diseased mice
compared to controls. In Fig. 2c, 3D models were recon-
structed. The panel at the left is the control tibia. In the
affected bones, arrows indicate cortical perforations. Sim-
ilar abnormal perforations could be observed in cortical
bone other than in the tibia. Osteolytic lesions caused by
MM to the vertebrae can be seen in virtual cross sections in
control mice (Fig. 3a, b) and in MM mice (Fig. 3c, d).
Similar to the tibia, trabecular bone mass is reduced
together with the disappearance of the inner microarchi-
tecture. In the diseased mouse, the bone in the vertebrae
Fig. 1 Growth kinetics of human MM cell lines in individual
RAG2
-/-cc
-/- mice. The increase in luciferase activity in individual
mice as a measure of the tumor load is shown: a RPMI-8226/S (n =
6), b U266 (n = 5). The thick (red) line in both graphs represents the
mean value from the mice in the respective groups. c, d Biolumi-
nescence images from a representative mouse (number 9), taken from
the ventral side (c) or from the dorsal side (d), with 2-week intervals
after inoculation of 5 9 10
6 U266 MM cells. Scaling of the images
differs between the images taken at different time points, as indicated,
in order to visualize all images in a single ﬁgure. Images are depicted
in false color ranging from blue to red. For weeks 3 and 5 the number
200 indicates a scaling of the light intensity ranging from 10–200
arbitrary units (a.u.)/pixel for weeks 7, 9, and 11 and the number
1,000 indicates a scaling ranging 10–1,000 a.u./pixel; for weeks 13
and 15 the number 10,000 indicates a scaling ranging 10–10,000 a.u./
pixel. (Color ﬁgure online)
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123also became less dense. Figure 4 illustrates representative
examples of outgrowth of bone in vertebrae as well as the
presence of abnormal calciﬁed tissue outside the ileum
(bottom panel), probably resulting from periosteal reac-
tions in the vicinity of tumors.
From these results it is obvious that micro-CT can image
the ﬁnal effect of the disease at the moment of death, i.e.,
abnormalities in the skeleton due to osteolytic lesions, but
it cannot prove the presence of myeloma cells themselves.
Therefore, these anatomical derangements were correlated
with histological observations. This is illustrated in Figs. 5
and 6, where a semitransparent 3D model of the caudal part
of the skeleton was reconstructed from virtual cross sec-
tions. The red areas indicate the structures that were
affected by MM as detected by BLI. The inserts show the
micro-CT sections, with arrows indicating bone defects.
The histological sections and speciﬁc immune staining for
myeloma cells (CD138 expression) conﬁrm the presence of
myeloma tumor cells at these locations, as shown in Fig. 6.
Histology
The presence of MM cells in the various bone specimens
was conﬁrmed by immunohistochemistry in detail in three
mice. The ﬁndings were correlated with the aberrations of
the skeleton detected by micro-CT (Table 2). Immuno-
staining is a sensitive method to show the presence of MM;
also, small foci of MM cells can be detected, provided that
the possible location of the tumor is identiﬁed, i.e., by BLI.
Comparison of the BLI signal and the immunohistochem-
ical conﬁrmation yielded an overall correlation for 20 out
of 23 specimens (Table 2). The histological slides also
reveal lumbar vertebrae completely ﬁlled with MM tumor,
with neighboring vertebrae that is completely normal
(Fig. 6j, k). Even within a femur areas with MM and areas
completely free of MM exist, again emphasizing the focal
growth behavior of this MM line in the mouse model
(Fig. 6a, l).
Table 1 Correlation of BLI-based localization of foci of MM growth





































































































1 RPMI-4 54     NS   B   
2 RPMI-5 54             
3 R2  63          B   
4 RPMI-1 48             
5 RPMI24 52  B           
6 RPMI-50/7  50          S   
 
U266              
7 U266-4  76  B        B  B 
8 U266-2  1st  74             
9 U266-5 105      B       
10 U266-2  2nd  105      S    B   
11  U266-II  12      S  S   
All mice received 5 9 10
6 MM cells at day 0 and developed the
disease. BLI signals were only observed in the skeleton. A gray cell in
the table indicates a correlation of the occurrence of a BLI signal and
the presence of skeletal aberrations in the same bone. ‘‘B’’ in a black
cell indicates the presence of a BLI signal and no aberrations in the
bone and ‘‘S’’ in a white cell indicates aberrations in the skeletal bone
but no BLI signal
NS no scans
Fig. 2 Micro-CT analysis of the tibia (representative example). Pixel
size is 13 lm. a Virtual cross section through control bone. b Cross
section of MM bone. Notice the loss of trabecular bone mass and
inner microarchitecture; the remaining bone is also less dense in the
tibia from an MM mouse. c 3D reconstruction of a representative
control (left) and an affected (right) tibia. Arrows indicate affected
areas where cortical perforations are present
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123Discussion
The present study reports a multimodal imaging analysis of
the effects caused by MM in immune-deﬁcient mice. Ini-
tially, during a lifetime, outgrowth of myeloma cells was
visualized by BLI. The brightness of the BLI signal is
proportional to the tumor load. Therefore, this warrants the
use of BLI to study the growth kinetics of MM and to
validate experimental therapeutic interventions in this
mouse model and underscores the value of imaging tech-
nology for this purpose reported by others [26, 27]. Ana-
lyzing the BLI images, we were able to localize the foci of
MM growth in an area of a few millimeters in a bone.
However, the presence of BLI signals indicates the pres-
ence of an MM tumor but it does not imply that the bone
environment is damaged at this speciﬁc location, nor can it
reveal the nature of the damage to the skeleton caused by
the inﬁltrating tumor cells. The occurrence of bone lesions
is a well-known symptom of MM, and therapeutic drugs,
e.g., bisphosphonates, are prescribed [28] to block disease-
induced osteoclast activity [29, 30], thus preventing oste-
olysis. In the humanized MM mouse model that uses
human fetal bone implants to facilitate outgrowth of
patient-derived primary MM cells, the bone resorbance by
the myeloma cells is well described [31]. Whether these
processes of osteolysis also occurred in our human MM
cell lines based mouse model was unknown.
Previously, micro-CT was used to detect bone lesions in
isolated tibiae in a murine model for MM [3]. In the present
study full skeletons were scanned as an initial screening to
determine the bones that were affected. Based on these
results, isolated bones were scanned with a high-resolution
and improved signal-to-noise ratio, resulting in more
detailed images. The occurrence of osteolytic bone lesions
(OBLs) in the human disease is associated with the pres-
ence of MM tumors and can be detected by CT analysis, as
conﬁrmed in this mouse model. The fact that micro-CT can
be used to visualize this process is in agreement with
reports from others [32, 33], but the combination of micro-
CT with BLI that we studied has the option to follow the
dynamics of these events during disease development as
well as after therapy. In both micro-CT studies (full skel-
etons and isolated bones) we observed several defects in
the diseased mice, which did not occur in normal control
Fig. 3 Micro-CT analysis of the effect of MM on the vertebral
column (representative example). Pixel size is 13 lm. a, b Two
orthogonal sections through the vertebrae of a control animal are
shown. c, d Two orthogonal sections through affected vertebrae of a
diseased mouse, where loss of trabecular mass and architecture is
present. Overall density of the remaining bone is smaller in MM
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123mice, with comparable gender and age. After ﬁnishing the
micro-CT experiments, the presence of MM tumors in the
bones was conﬁrmed by immunohistochemistry in three
selected mice. In some cases foci of MM cells were present
in the histological slices, although they had not caused any
lesions that were detectable by micro-CT. One possible
explanation for this discrepancy might be the fact that
spatial resolution is lower in micro-CT than in histology
and that the size of the lesions was too small for micro-CT.
However, histology might miss some derangements due to
the cutting bias. This latter phenomenon may also interfere
while making a correlation between the results from the
two techniques. In addition, the presence of regions of bone
destruction as revealed by micro-CT was compared with
the results previously obtained from BLI signals in living
mice. When both BLI and micro-CT signals are positive,
this observation implies that the MM cells caused their
anatomical damage at the same locations where they were
growing. This is the case in most of the regions, despite the
fact that both signals were measured at different time
points. In total 82% of all areas correlated (Table 1), with
some skeleton parts having a higher correlation (sacrum
and femora) and some skeleton parts having a lower cor-
relation (sternum and humerus); but this is highly depen-
dent on the high incidence of MM tumors present in those
bones and unlikely to be statistically signiﬁcant.
In the regions where the BLI signal was positive, no
aberrations were observed by micro-CT. This might imply
that the cells, although present, did not yet induce any
visible anatomical destructions. We already discussed that
probably a minimal amount of MM cells should be present
for a certain period of time to cause some damage to the
bone, which is a slow process. Areas with severe cortical
bone defects (derangements as well as perforations), such
as the sacrum and ileum in the pelvic area as well as the
femora, were highly correlated with a strong BLI signal,
indicative for a high tumor load.
The absence of a BLI signal combined with destruction
seen by micro-CT might suggest that the MM cells secrete
cytokines or other soluble factors that distribute throughout
the circulation and may cause skeletal destruction (by
stimulation of osteoclasts) not associated by cellular inﬁl-
tration. In addition, the light absorption by tissues has been
determined as a limitation to BLI sensitivity [26], which is
therefore depth-dependent. Superﬁcial small tumors can be
as bright as deeply located large tumors. This may account
for some differences in the observations from the two
imaging techniques. In human disease the MM-associated
OBL results from an uncoupling of osteoclast–osteoblast
activity, in which factors, e.g., NFjB and osteoprotegerin
(OPG), regulated by Wnt3a, play crucial roles [34]. On the
other hand, dickkopf-1 (DKK-1) produced in cell lines or
derived from bone marrow sera from MM patients, was
reported to suppress Wnt-3-induced expression of OPG in
osteoblasts [35]. The cell lines U266 and RPMI that we
used constitutively produced a soluble Wnt inhibitor,
secreted Frizzled-related protein 2 (sFRP-2), but not DKK-
1[ 35]. This opens up the possiblity of studying the anti-
tumor potential of drugs that interfere with these pathways
and how this affects the changes in the bone microenvi-
ronment. Another reason for us to establish a humanized
MM model is in view of developing a model that would
enable us to explore possibilities for adoptive immune
Fig. 4 External abnormal calciﬁcations: calciﬁed protuberance of a
vertebra. Pixel size is 13 lm. a, b Representative cross sections
showing the inner structure of the outgrowth. c 3D model. Outgrowth
is indicated with an arrow. d (cross-section through the affected area)
and e (3D model) Calciﬁed tissue (arrow) that is formed close to the
surface of the ilium, which is not observed in a healthy skeleton. Also
notice the rough surface of the bone
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123Fig. 5 Semitransparent 3D model of a mouse skeleton built from a
full-body scan with 35 lm pixel size. Dark (red) areas in the skeleton
indicates places affected by tumor activity. Inserts represent micro-
CT sections with damaged bones. Letters correspond to histological
sections shown in Fig. 6. (Color ﬁgure online)
Fig. 6 Histology. Photographs
of parafﬁn-embedded sections
of various bones from the
skeleton (femur, tibia, and
vertebrae) of the mouse
depicted in Fig. 5 (a–i), stained
with hematoxylin–eosin (a, d, g,
j, k, l) or after immunostaining
for expression of CD138
antigen (b, e, h, c, f, i). j–l
Examples of MM-diseased
bones with adjacent bones
displaying normal morphology.
Brown (dark) color indicates the
presence CD138-positive cells.
Areas indicated by the squares
in b, e, and h are enlarged in c,
f, and i, respectively.
Magniﬁcation is 925 or 9400
as indicated. (Color ﬁgure
online)
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123therapy on the basis of minor HLA antigens (mHags) [36].
Certain mHags are exclusively expressed on patient
hematopoietic and malignant cells that can be utilized for
speciﬁc targeting of myeloma cells after human histo-
compatibility leukocyte antigen (HLA)–matched alloge-
neic stem cell transplantation (allo-SCT). Earlier we
identiﬁed two mHags that can serve as targets for human
cytotoxic T lymphocytes [5, 37]. Cloning of the corre-
sponding T-cell receptor will open the possibility to further
develop patient-tailored immunotherapy [7].
In summary, multimodal imaging analysis of human
myeloma growth in the RAG2
-/-cc
-/- mouse revealed a clear
correlation between the BLI signal, micro-CT analysis, and
immunohistochemistry and in this respect strongly resem-
bles the human disease. The model has potential for the
study of the biology of human myeloma and for preclinical
evaluation of new therapeutic approaches aimed at coun-
teracting MM-induced bone lesions.
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